The company behind the “sub-$10” tease

Absci Corporation (ABSI) is the stock behind Alexander Green’s Oxford Club pitch for “my number one microcap for today’s market,” a company he frames as sitting where artificial intelligence meets healthcare. The ad leans on the idea that Absci is virtually invisible to most investors and still trades under $10 a share. The reveal is real: Absci is an AI-powered drug discovery company, and the underlying business is more interesting than the “undiscovered microcap” framing lets on. The details are in our Oxford Club’s ‘Sub-$10 AI Drug Stock’ — Absci, the Stock… article.

The core idea is elegant. Absci takes proteins, the biological machines that do most of the work in the human body, and converts them into a digital form its generative AI can analyze. Traditional drug discovery is a grind of screening thousands of compounds and hoping one sticks. Absci’s approach lets its models search a far larger space of possible designs and zero in on the most promising candidates before anything ever enters a lab. That is a genuine technological bet, not a marketing slogan.

Real partners, real money

The partnership list is the strongest evidence that this is a real company, and it is worth taking seriously. Merck signed a drug discovery deal with Absci in 2022 worth up to about $610 million in milestone payments. AstraZeneca followed in 2023 with a deal worth up to about $247 million to apply the platform to cancer drugs. More recently, Absci struck a hardware collaboration with AMD that came with a $20 million investment in January 2025, and Eli Lilly made a $40 million strategic investment tied to the lead program.

None of those names is fabricated, and the AMD investment is public record. That is a meaningful distinction in a corner of the market where promotional picks are often far more speculative. We map the wider field in our AI drug discovery companies piece, but the short version is that Absci has the kind of partner roster a real platform earns, not one an ad can invent.

The lead asset and the timeline

The lead asset is ABS-201, an antibody engineered with an extended half-life that targets pattern hair loss and is also being tested in endometriosis. The June safety readout looked encouraging enough to push the stock toward $12 from a trough near $2 earlier in the year. The catalyst calendar is defined: preliminary proof-of-concept data is expected in the second half of 2026, fuller proof in early 2027, a Phase 2 in endometriosis before year end, and a hoped-for Phase 3 in hair loss as soon as late 2027.

The hair loss angle is genuinely interesting. A well-tolerated, longer-acting antibody for a condition that affects an enormous number of people would be a meaningful market. A useful yardstick is Veradermics, which is in late Phase 3 with an oral hair-loss treatment and carries a market cap around $5 billion on that single asset.

The royalty pitch, and the numbers that don’t match

The promo’s big claim is that Absci will be “the world’s next big royalty business,” where pharma partners do the heavy lifting and Absci simply collects royalties. That is how this corner of biotech actually works, and it is fair to describe the potential that way. The timing is the problem: royalties arrive when drugs are on the market, and Absci is several clinical years from that point. The first real test is not a royalty check; it is whether the ABS-201 proof-of-concept data lands in the second half of 2026.

The numbers also deserve a hard look. Green describes a market cap “around 750 million dollars,” but Absci is worth about $1.69 billion today. The “sub-$10 microcap” story was true in 2022 and 2023, when the stock traded between roughly $1.60 and $5. A buyer at $10.71 is not discovering the company before anyone else; they are paying roughly twice the valuation the ad implies. The royalty thesis is reasonable, but the bargain framing no longer matches the price tag. We unpack that royalty model in our best royalty stocks explainer.

The fine print worth knowing

Two details in the ad deserve a footnote. First, the “$100,000 of my own money” claim has been repeated since 2022 and 2023, so it reads as recycled conviction rather than a fresh 2026 investment at current prices. Second, the pitch leans on an older “NVIDIA partner” credential when the more recent and more material hardware relationship is the AMD collaboration. Neither point changes the underlying company, but both belong in the picture for a buyer deciding whether the “undiscovered” framing still applies. The subscription itself runs $1,995 a year with a 60-day partial refund, minus a 10% refund fee.

Ready to see the research? Click here to access Alexander Green’s report.

NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.